Clinical trials
![]() Durvalumab (MEDI4736) After chemoRadioTherapy for NSCLC patients |
![]() Nivolumab and Ipilimumab +/- UV1 vaccination as second line treatment in patients with malignant mesothelioma |
Immunotherapy combined with extensive radiotherapy for the treatment of stage IV non-small cell lung cancer (COM-IT-2) |
Norwegian Pancreatic Cancer Trial (NorPACT)-2: |
|